Strategy
The Genetically Modified Organisation
New research points to how leaders can accelerate their firm’s evolution
In a market characterised by change it is a truism that life science companies must adapt to survive Yet such change is notoriously difficult as the extinction of our industrys great names shows Between and for example the Pharmaceutical Research and Manufacturers of America PhRMA lost per cent of its members This attrition suggests that CEOs la...
Competing on Alignment
The most powerful strategic management tool is also the most misunderstood Consultants often use military analogies comparing competitors to enemies and strategies to battle plans This tradition arose in the early days of strategic planning in the s when many executives and writers had personal experience of military life But for the life scienc...
Sustainable Antibiotics
Evolving pharmaceutical supply chain to ensure effectiveness
Tackling the challenge of supply chain security in the face of antibiotic resistance Antibiotic resistance Antimicrobial Resistance AMR also called antibiotic resistance is a reality AMR renders antibiotics ineffective meaning they can no longer fight bacterial infections and ultimately become useless Every year AMR is responsible for nea
Prospects for Personalised Medicines in the Asia-Pacific Region
Personalised Medicine PM is the wave of the future but will the waves be bathing the shores of AsiaPacific with the same market force as they do on either side of the Atlantic Personalised medicine also called precision medicine encompasses treatment approaches that target the medicines used based on the characteristics of the individual patient ra...
Microfluidic Organs-on-a-Chip
The patent landscape
Traditional methods of drug discovery in particular the use of animal testing suffer from many limitations including a the length of time and high costs associated with animal trials b the loss of animal lives and c the failure of animal tests to accurately predict human responses Twodimensional D cell cultures have shown value in biomedical rese...
Regulatory Considerations for Forced Degradation Studies to Assess the Stability of Drugs
Quality safety and effectiveness are the most important attributes of drugs and pharmaceuticals Because of its key role in public health the pharmaceutical industry has always been a comparatively highly regulated industry Until the end of nd World War the quality of pharmaceutical products was determined mainly by assaying the content of their act...
What are the 10 Hot Topics in Pharmaceutical Operational Excellence for 2015?
Status Quo Analysis from an Operations Management Perspective
The competence centre for Operational Excellence OPEX at the Institute of Technology Management at the University of St Gallen Switzerland ITEMHSG has focused its research for more than ten years on the challenges faced by pharmaceutical companies in their pursuit of Operational Excellence Over time the researchers have been able to sustain a datab...
The Lasting Advantage
Why are some firms more competitive than others This is the central question of my research in the field of strategic management Decades of research in both the life sciences and other industries have converged to suggest there are perhaps three overarching reasons The first is the most obvious what academics call the ResourceBased View of the Firm...
Bioprinting
The patent landscape
Additive manufacturing or D printing as known more widely is revolutionising the manufacture and distribution of products With the expirations of the basic additive manufacturing patents anyone can purchase an inexpensive printer and replicate products But these products are often protected by various forms of intellectual property laws
Creating and Sustaining Cultural Change by Focusing on Operational Excellence
Over the past decade the importance of Operational Excellence OPEX in the pharmaceutical industry has grown significantly A mere copy and paste from successful automotive excellence programmes does not work for the pharmaceutical structural requirements in the long run Friedli et al This has been realised by most of the pharma companies in the pas...
